Novartis withdrew its European Medicines Agency application for Pluvicto as a pre-chemotherapy treatment for PSMA-positive metastatic castration-resistant prostate cancer.3
Despite the EU regulatory setback and bispecific competition, Novartis maintains its $5 billion peak sales target for Pluvicto.123
The news was reported on April 28, 2026, highlighting Novartis's confidence in the drug's potential.13
Sources:
1. https://www.fiercepharma.com
2. https://www.newsnow.co.uk/h/Industry+Sectors/Pharmaceuticals
3. https://www.fiercepharma.com/pharma/novartis-stands-5b-pluvicto-goal-despite-european-regulatory-setback-bispecific-competition